Should targeting immunosuppression, immunoregulation or remyelination be used to treat inflammatory neuropathies?
Créange
Alain
A
D051152:Clusterin / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000592:standards* / Q000627:therapeutic use; D007165:Immunosuppression Therapy / Q000379:methods / Q000592:standards*; D009186:Myelin Sheath / Q000187:drug effects* / Q000276:immunology; D009416:Nerve Regeneration / Q000187:drug effects* / Q000276:immunology; D009443:Neuritis / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D010523:Peripheral Nervous System Diseases / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D012583:Schwann Cells / Q000187:drug effects / Q000276:immunology; D016212:Transforming Growth Factor beta / Q000187:drug effects / Q000276:immunology
C495242:CLU protein, human; D051152:Clusterin; D007155:Immunologic Factors; D016212:Transforming Growth Factor beta